Manila Times Business
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June 1, 2026, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 145,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee app
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Keystone Acquisition Corp. Announces Pricing of $250 Million Initial Public Offering
2h ago
Moderna Launches Moderna Direct with "eCommerce Powered by FFF Enterprises™”
2h ago
ATN International, Inc. Completes Initial Closing on the Sale of its Towers and Updates 2026 Outlook
2h ago
Neuronetics Appoints Robert Greene as Senior Vice President Sales
2h ago